Qualitek Labs Ltd

Q4 FY26Commercial Services & Supplies

Qualitek Labs Ltd Q4 FY26 Results & Presentation Highlights: Revenue ₹70.3 Cr, PAT ₹9.8 Cr

Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹621

Market cap₹683 Cr

P/E46.6

Updated25 Sept 2026

Read4 min read

Based on Qualitek Labs Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Quarter (H2 FY26) Revenue: ₹70.3 Cr, up 56% YoY from ₹45.2 Cr in H2 FY25. Quarter (H2 FY26) Consolidated Results: - EBITDA: ₹18.1 Cr, +102% YoY - EBITDA Margin: 26% (up from 20% YoY) - PAT: ₹9.8 Cr, +143% YoY - PAT Margin: 14% (up 5% YoY) - Quarter (H2 FY26) St

From Qualitek Labs Ltd's Q4 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

Quarter (H2 FY26) Revenue: ₹70.3 Cr, up 56% YoY from ₹45.2 Cr in H2 FY25.
Quarterly Sequential Growth: Revenue increased 30% vs H1 FY26 ₹54.2 Cr.
Quarter (H2 FY26) EBITDA: ₹18.1 Cr, up 102% YoY, 61% sequentially.
Quarter (H2 FY26) PAT: ₹9.8 Cr, up 143% YoY, 106% sequentially.
Full Year FY26 Consolidated Revenue: ₹124.5 Cr, up 77% YoY from ₹70.2 Cr FY25.
Full Year FY26 Standalone Revenue: ₹67.6 Cr, up 47% YoY from ₹45.9 Cr FY25.
Explicit Outlook:

2 more points management made on revenue & sales performance

Profitability & Margins

Quarter (H2 FY26) Consolidated Results:
EBITDA: ₹18.1 Cr, +102% YoY
EBITDA Margin: 26% (up from 20% YoY)
PAT: ₹9.8 Cr, +143% YoY
PAT Margin: 14% (up 5% YoY)
Quarter (H2 FY26) Standalone Results:
EBITDA: ₹10.0 Cr, +39% YoY
EBITDA Margin: 26% (down 3% YoY)
PAT: ₹5.2 Cr, +45% YoY
PAT Margin: 13% (down 1% YoY)
Margin Outlook (FY27):

2 more points management made on profitability & margins

See what Qualitek Labs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

FY2025-26 Capex of INR 51.3 Cr invested in:
Acquisition of Food testing lab in Mumbai
Operationalized 2nd lab in Bhubaneshwar
Capacity expansion of Pharma and Food labs in Panchkula and Chennai
New scope addition in Transport and Defence segments
Setting-up VOC testing facility in Noida
Acquired land & building in Barwala, Panchkula for future expansion
FY2026-27 planned Capex of INR 63 Cr includes:
M&A opportunities in Pharma, Food, Electricals & Electronics segments
Further capacity expansion of Food labs in Mumbai, Chennai, Bhubaneshwar
Accreditation for Inspections, Audit, Certification, and Fumigation business
Geographic expansion in Transport and Minerals segments
New revenue streams: EMI/EMC lab in Pune and Analytical lab in Noida
Status:
Bhubaneshwar 2nd lab operational (FY25-26)
Noida lab operational in Electricals & Electronics (by 2024-26)

2 more points management made on capital expenditure plans

Top-ranked in Commercial Services & Supplies

Ranked on what management guided this quarter

5x potential

1Bluspring Enter.₹1.8K Cr

Rev 1Mar 1

2Anlon Tech₹558 Cr

Rev 1Mar 3

3₹99 Cr

Rev 1Mar 3

4₹3.8K Cr

Rev 2Mar 1

5₹904 Cr

Rev 2Mar 2

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The investor presentation does not explicitly mention any new fundraising through debt or equity during the period.
There is no specific reference to issuance of shares, rights issues, or fresh borrowings.
Debt-Equity Ratio data is provided (Page 13), showing values of 2.37 in FY23 reducing to 1.25 in FY26, indicating a reduction in relative debt.
Finance cost increased from ₹0.69 Cr in FY23 to ₹4.81 Cr in FY26 (Page 11), suggesting increased interest expenses but no explicit mention of new debt raised.

2 more points management made on fundraising & capital structure

See what Qualitek Labs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation of Qualitek Labs Limited does not explicitly report or mention any figures or details related to: - Order book - Order inflow - Pending orders No specific data or commentary concerning current or projected orders is provided in the presentation. The focus is mainly on financial results, growth metrics, operational achievements, expansion plans, and strategic priorities without reference to order pipeline or backlog status.

Others in Commercial Services & Supplies this season

IIRM Holdings India Ltd (Q4 FY26)
Q4 FY26 Revenue from Operations: ₹651.32 million, up 15.37% YoY from ₹564.6 million in Q4 FY25 (Page 8, 28). Key investor presentation takeaways from IIRM Holdi
Kapston Services Ltd (Q4 FY26)
Q4 FY26 Revenue: ₹216.47 Crores . Key investor presentation takeaways from Kapston Services Ltd's Q4 FY26 investor presentation — and how it ranks against secto
NDR INVIT Trust (Q4 FY26)
Year-on-year (YoY) revenue growth for Q4 FY26: 30% (noted on page 4) . Key investor presentation takeaways from NDR INVIT Trust's Q4 FY26 investor presentation
Smartworks Coworking Spaces Ltd (Q4 FY26)
Revenue from operations for Q4FY26: INR 5,197 Mn, a 45% YoY increase from INR 3,584 Mn in Q4FY25 (Page 34). Key investor presentation takeaways from Smartworks

Compare:vs Redington vs Firstsour.Solu.vs eClerx Services Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Qualitek Labs Ltd Q4 FY26 results?

What is Qualitek Labs Ltd share price analysis?

Qualitek Labs Ltd currently shows a neutral. The stock trades at a P/E of 46.6 with a market cap of ₹683 Cr. Investors should review the full earnings analysis for detailed insights.

Is Qualitek Labs Ltd planning capital expenditure?

FY2025-26 Capex of INR 51.3 Cr invested in: - Acquisition of Food testing lab in Mumbai - Operationalized 2nd lab in Bhubaneshwar - Capacity expansion of Pharma and Food labs in Panchkula and Ch

Keep Qualitek Labs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.